At the foundation of the long-term strategic positioning is the development of CLONICEL^®, the company’s lead product. CLONICEL^® is a patented extended release formulation of clonidine hydrochloride, a drug currently approved for hypertension but also used by clinicians for a large number of conditions related to hyperadrenergia, including ADHD. CLONICEL^® was developed and patented by Dr. Horacek at the Center for Neurological Health in Learning (CNHL), in Charlotte, NC. The formation of Addrenex is a logical extension of Dr. Horacek’s work and will make this drug available to a much wider patient population with various medical conditions related to adrenergic dysregulation.

CLONICEL^® is being developed to address the unmet need in the marketplace for a longer lasting, better tolerated version of clonidine. Addrenex is developing CLONICEL^® for both hypertension and ADHD.